Our site uses cookies to offer a better navigation functionality, including "third party" cookies and "profiling cookies" designed to send on-line commercial communications in line with the preferences expressed by the user while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here to disable them. Upon proceeding with browsing this website, you will be consenting to the use of cookies.

Humanized monoclonal antibodies

3 mAbs (hematological malignancies and/or solid tumors)

New humanized monoclonal antibodies (mAbs), against newly identified antigen oncology targets, acting through Antibody Dependent Cell Cytotoxicity (ADCC) or as Antibody Drug Conjugated (ADC-antibody linked to a toxin) will be developed.

Selective and high affinity mAbs are being generated by an external partner.

Characterization of these mAbs in terms of binding characteristics, in vitro efficacy (ADCC, cytotoxicity, internalization), in vivo efficacy (xenograft models) and exploratory toxicology are ongoing.

Menarini will be responsible for: (i) development and commercial manufacturing, (ii) regulatory non-clinical development, (iii) clinical development phase I to phase III and (iv) regulatory submission to main Regulatory Agencies.

According to the agreement with OBT for the development and commercialization of 5 Antibodies, 2 of them are in Phase I  clinical trial  (MEN1112)  and Preclinical development (MEN1309)

Press Release 29/10/2012

Therapeutic Areas

 

Discover all of Menarini's products marketed in Italy.

READ MORE »

Diagnostics

 

Advanced Technology

READ MORE »

The Menarini Group

 

Discover the leading Italian pharmaceutical company in the world.

READ MORE »

Quality first

 
 

Quality: point of departure and arrival for our drugs.

READ MORE »